Evidence map›Paper›PMID 32612272›Full record

Trial reportScientific reports2020

Analysis of the StoRM cohort reveals physical activity to be associated with survival in metastatic breast cancer.

Lidia Delrieu, Emmanuelle Jacquet, Céline Segura-Ferlay, Ellen Blanc, Olivia Febvey-Combes, Christine Friedenreich, Gilles Romieu, William Jacot, Maria Rios, Pierre-Etienne Heudel and 14 more

Open access · goldAbstract readMulticenter StudyRandomized Controlled Trial
In one paragraph

Trial report in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 4 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 4 syntheses or guidelines pooled it, 20 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Diets Rich inNutrients · 2026
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. A review of the impact of energy balance on triple-negative breast cancer.Journal of the National Cancer Institute. Monographs · 2023
    Review
  16. Article
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

24 authors at 13 institutions in 2 countries.

Lidia Delrieu *Laboratory of Motor Biology (LIBM), EA7424, Vascular Biology and Red Blood Cell Team, Claude Bernard Lyon 1 University, Villeurbanne, France.
Emmanuelle Jacquet *Oncology and Blood Diseases Department, Joseph Fourier University, University Hospital Center, Grenoble, France. ejacquet1@chu-grenoble.fr.
Céline Segura-FerlayDirection of Clinical Research and Innovation (DRCI), Centre Léon Bérard, Lyon, France.
Ellen BlancDirection of Clinical Research and Innovation (DRCI), Centre Léon Bérard, Lyon, France.
Olivia Febvey-CombesDirection of Clinical Research and Innovation (DRCI), Centre Léon Bérard, Lyon, France.
Christine FriedenreichDepartment of Cancer Epidemiology and Prevention Research, CancerControl Alberta, Alberta Health Services, Calgary, AB, Canada.ORCID http://orcid.org/0000-0002-4783-1966
Gilles RomieuInstitut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France.
William JacotInstitut du Cancer de Montpellier (ICM) Val d'Aurelle, Montpellier, France.ORCID http://orcid.org/0000-0001-7834-061X
Maria RiosDepartment of Medical Oncology, Cancer Institute of Lorraine - Alexis Vautrin, Vandoeuvre Les Nancy Cedex, France.
Pierre-Etienne HeudelOncology Department, Centre Léon Bérard, Lyon, France.
Célia Roemer-BecuweOncology Center of Gentilly, Nancy, France.
Christelle JouannaudMedical Oncology Service, Jean Godinot Institute, Reims, France.
Olivier TredanOncology Department, Centre Léon Bérard, Lyon, France.
Loïc ChaigneauMedical Oncology Service, University Regional Hospital Center, Besançon, France.ORCID http://orcid.org/0000-0002-4938-9470
Monica ArnedosDepartment of Medical Oncology, Gustave Roussy Cancer Campus, Villejuif, France.
Hubert OrfeuvreMedical Oncology Service, Fleyriat Hospital Center, Bourg en Bresse, France.
Nathalie Quenel-TueuxMedical Oncology Department, Bergonié Institute, Bordeaux, France.
Jean-Philippe JacquinMedical Oncology Department, Lucien Neuwirth Oncology Institute, Saint Priest en Jarez, France.
Jean-Marc FerreroMedical Oncology Department, Antoine Lacassagne Center, Nice, France.
Isabelle MoulletMedical Oncology Department, Sauvegarde Clinic, Lyon, France.
Sophie Abadie-LacourtoisieWestern Cancer Institute, Paul Papin site, Angers, France.
Frédérique Penault-LlorcaJean Perrin Center, and UMR INSERM 1240 IMoST, Clermont-Ferrand, France.
David CoxCancer Research Center of Lyon, INSERM U1052, Centre Léon Berard, Lyon, France.
Thomas BachelotOncology Department, Centre Léon Bérard, Lyon, France.
Centre Léon Bérard · FRInserm · FRInstitut de Recherche en Cancérologie de Montpellier · FRAlberta Health Services · CACentre Antoine Lacassagne · FRCentre Hospitalier Universitaire de Besançon · FRInstitut Bergonié · FRInstitut de Cancérologie de Lorraine · FRInstitute Cancer De La Loire Lucien Neuwirth · FRInstitut Gustave Roussy · FRInstitut Jean Godinot · FRUniversité Claude Bernard Lyon 1 · FRUniversité Joseph Fourier · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Benefits of physical activity are widely demonstrated for early stage cancers but few studies have focused on metastatic disease. The purpose of this study was to determine the impact of physical activity on survival in patients with metastatic breast cancer. We conducted a secondary analysis of the national, multicentric, non-randomized, prospective cohort SNPs to Risk of Metastasis (StoRM) study. The level of physical activity was self-reported at inclusion and divided into three categories of physical activity: light level, moderate level, and vigorous level. Overall, 833 patients (56.2%) completed the physical activity questionnaire at baseline on average physical activity during the previous year: 11.6% had a light level of physical activity, 69.0% achieved moderate levels of physical activity and 19.3% reported vigorous levels of physical activity. After adjustment for confounding, physical activity was not statistically significantly associated with overall survival in the whole population. Subgroup analysis identified that both vigorous and moderate physical activity were associated with statistically significantly improved overall survival compared to light physical activity level only in the HER2 positive subgroup (HR 0.23; 95% CI 0.07-0.70, p = 0.01 and HR 0.38; 95% CI 0.15-0.96, p = 0.04). Physical activity done during the previous year was associated with survival in HER2 positive metastatic breast cancer patients. These results suggest that overall survival in metastatic breast cancer patients could be improved through physical activity which should be considered as a complementary intervention for these individuals. The study showed that moderate/vigorous levels of physical activity were associated with better overall survival, and that these associations remained statistically significant in multivariate analysis in the HER2 positive subgroup. These results have clinical relevance and justify the recommendations for physical activity interventions in metastatic breast cancer.

Indexed as

ExerciseAgedAnthropometryBody Mass IndexBreast NeoplasmsData Interpretation, StatisticalErb-b2 Receptor Tyrosine KinasesFemaleHumansMiddle AgedMultivariate AnalysisNeoplasm MetastasisPolymorphism, Single NucleotidePrognosisProportional Hazards ModelsProspective StudiesERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Identifiers

PMID32612272
PMCPMC7329808
OpenAlexW3039044006

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.